Gene therapy sponsors may decide not to submit a long-term follow-up (LTFU) protocol to the US FDA if they feel if it is not needed, but they should do so at their own risk, as they could potentially face a clinical hold, the agency says.
In one of six gene therapy draft guidances published July 11, the agency provided a series of recommendations regarding LTFU...



